• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

土耳其人群中细胞色素P450酶2C19和2D6缺陷等位基因的低频率

Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.

作者信息

Aynacioglu A S, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp S O, Roots I, Brockmöller J

机构信息

Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University, Berlin, Germany.

出版信息

Clin Pharmacol Ther. 1999 Aug;66(2):185-92. doi: 10.1053/cp.1999.v66.100072001.

DOI:10.1053/cp.1999.v66.100072001
PMID:10460072
Abstract

BACKGROUND AND OBJECTIVES

The genetically polymorphic cytochrome P450 enzymes 2Cl9 (CYP2Cl9) and 2D6 (CYP2D6) contribute to the metabolism of about 30% of all drugs. For analysis of the ethnic-related differences in drug disposition and as a preparation for routine genotyping, we examined CYP2C19 and CYP2D6 mutations in a large Turkish population.

METHODS

CYP2C19 and CYP2D6 alleles were determined with use of genomic deoxyribonucleic acid from 404 unrelated Turkish individuals. CYP2C19 alleles *1 to *5 and CYP2D6 alleles *1 to *12, and *14, *15, and *17 were measured by polymerase chain reaction-restriction fragment length polymorphism assays.

RESULTS

From 404 subjects genotyped for CYP2C19, allele frequencies of CYP2C191 (wt), CYP2C192 (ml), and CYP2C193 (m2) were 0.88, 0.12, and 0.004, respectively; mutations m3 and m4 were not found. Four individuals (1.0%) were predicted to be poor metabolizers (CYP2C192/2), a significantly lower frequency compared to Middle European populations. Among 404 subjects genotyped for CYP2D6, most frequent alleles were CYP2D61 (allele frequency 0.37), *2 (0.35), *4 (0.11), *10 (0.06), duplications *1x2, *2x2, or *4x2 (0.06), *5 (0.01), and *17(0.01). Overall, six subjects (1.49%) were predicted to be CYP2D6 poor metabolizers, and 35 subjects (8.66%) were predicted to be ultrarapid metabolizers as a result of CYP2D6 gene duplications.

CONCLUSION

Obviously, within Europe there is a north-south gradient, with decreasing frequency of poor metabolizers of CYP2C19 and CYP2D6 to the south and a corresponding increase of ultrarapid metabolizers of CYP2D6. As in other white groups, only CYP2C19*2 plays a relevant role for the CYP2C19 poor metabolizer phenotype. The mutational spectrum of CYP2D6 indicated partial ethnic relationships to Asian and African populations.

摘要

背景与目的

基因多态性细胞色素P450酶2C19(CYP2C19)和2D6(CYP2D6)参与了约30%的药物代谢。为分析药物处置方面的种族差异并为常规基因分型做准备,我们在一大群土耳其人群中检测了CYP2C19和CYP2D6突变。

方法

使用来自404名不相关土耳其个体的基因组脱氧核糖核酸测定CYP2C19和CYP2D6等位基因。通过聚合酶链反应-限制性片段长度多态性分析检测CYP2C19等位基因1至5以及CYP2D6等位基因1至12、*14、15和17。

结果

在404名进行CYP2C19基因分型的受试者中,CYP2C191(野生型)、CYP2C192(m1)和CYP2C193(m2)的等位基因频率分别为0.88、0.12和0.004;未发现m3和m4突变。4名个体(1.0%)被预测为慢代谢者(CYP2C192/2),与中欧人群相比频率显著更低。在404名进行CYP2D6基因分型的受试者中,最常见的等位基因是CYP2D61(等位基因频率0.37)、*2(0.35)、*4(0.11)、10(0.06)、重复型1x2、2x2或4x2(0.06)、5(0.01)和17(0.01)。总体而言,6名受试者(1.49%)被预测为CYP2D6慢代谢者,35名受试者(8.66%)由于CYP2D6基因重复被预测为超快代谢者。

结论

显然,在欧洲存在南北梯度差异,CYP2C19和CYP2D6慢代谢者的频率向南降低,而CYP2D6超快代谢者相应增加。与其他白种人群一样,只有CYP2C19*2对CYP2C19慢代谢者表型起相关作用。CYP2D6的突变谱表明与亚洲和非洲人群存在部分种族关联。

相似文献

1
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.土耳其人群中细胞色素P450酶2C19和2D6缺陷等位基因的低频率
Clin Pharmacol Ther. 1999 Aug;66(2):185-92. doi: 10.1053/cp.1999.v66.100072001.
2
Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.希腊人群中药物代谢酶CYP2D6、CYP2C9、CYP2C19和CYP3A5的基因多态性
Fundam Clin Pharmacol. 2007 Aug;21(4):419-26. doi: 10.1111/j.1472-8206.2007.00510.x.
3
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.俄罗斯人群中药物代谢酶CYP2C9、CYP2C19、CYP2D6、CYP1A1、NAT2及P-糖蛋白的多态性
Eur J Clin Pharmacol. 2003 Aug;59(4):303-12. doi: 10.1007/s00228-003-0606-2. Epub 2003 Jul 15.
4
CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.阿什肯纳兹犹太人群体中CYP2C9、CYP2C19和CYP2D6等位基因频率
Pharmacogenomics. 2007 Jul;8(7):721-30. doi: 10.2217/14622416.8.7.721.
5
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.坦桑尼亚黑人人群中CYP2D6和CYP2C19的表型和基因型
Br J Clin Pharmacol. 1999 Sep;48(3):395-401. doi: 10.1046/j.1365-2125.1999.00019.x.
6
Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.克罗地亚人群中细胞色素P450的基因多态性:CYP2C9、CYP2C19和CYP2D6
Croat Med J. 2003 Aug;44(4):425-8.
7
Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.以色列不同种族群体中CYP2C19和CYP2D6的多态性。
Am J Pharmacogenomics. 2004;4(6):395-401. doi: 10.2165/00129785-200404060-00006.
8
Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.包括精神疾病患者在内的东非和南非人群中CYP2D6和CYP2C19的基因多态性。
Eur J Clin Pharmacol. 2001 Apr;57(1):11-7. doi: 10.1007/s002280100282.
9
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.意大利人群中CYP2C9、CYP2C19和CYP2D6的等位基因及基因型频率
Pharmacol Res. 2004 Aug;50(2):195-200. doi: 10.1016/j.phrs.2004.01.004.
10
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.多态性药物氧化的地理/种族差异。细胞色素P450(CYP)2D6和2C19的现有知识状况。
Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005.

引用本文的文献

1
Analysis of Gene Variant Frequencies in Iranian Population.伊朗人群基因变异频率分析
Iran J Med Sci. 2025 May 1;50(5):351-358. doi: 10.30476/ijms.2024.102645.3570. eCollection 2025 May.
2
Role of genetic polymorphisms in clopidogrel response variability: a systematic review.遗传多态性在氯吡格雷反应变异性中的作用:系统评价。
Open Heart. 2023 Nov;10(2). doi: 10.1136/openhrt-2023-002436.
3
Pain Management in Children Admitted to the Emergency Room: A Narrative Review.急诊室收治儿童的疼痛管理:一项叙述性综述
Pharmaceuticals (Basel). 2023 Aug 18;16(8):1178. doi: 10.3390/ph16081178.
4
genetic polymorphisms in Saudi systemic lupus erythematosus patients: A cross-sectional study.沙特系统性红斑狼疮患者的遗传多态性:一项横断面研究。
Saudi Med J. 2023 Mar;44(3):237-245. doi: 10.15537/smj.2023.44.3.20220581.
5
CYP2C19 gene polymorphism in Ningxia.宁夏 CYP2C19 基因多态性。
Pharmacol Rep. 2023 Jun;75(3):705-714. doi: 10.1007/s43440-023-00473-5. Epub 2023 Mar 13.
6
Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.定量蛋白质组学在转化吸收、分布、代谢和排泄及精准医学中的应用。
Pharmacol Rev. 2022 Jul;74(3):769-796. doi: 10.1124/pharmrev.121.000449.
7
Pharmacogenetics in Primary Headache Disorders.原发性头痛疾病中的药物遗传学
Front Pharmacol. 2022 Feb 10;12:820214. doi: 10.3389/fphar.2021.820214. eCollection 2021.
8
Frequencies of CYP2D6 genetic polymorphisms in Arab populations.阿拉伯人群 CYP2D6 基因多态性的频率。
Hum Genomics. 2022 Feb 5;16(1):6. doi: 10.1186/s40246-022-00378-z.
9
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.群体药物基因组学:种族地理差异及精准公共卫生的机遇更新。
Hum Genet. 2022 Jun;141(6):1113-1136. doi: 10.1007/s00439-021-02385-x. Epub 2021 Oct 15.
10
Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.亚洲人群中他莫昔芬治疗的药物遗传学:从遗传多态性到临床结局。
Eur J Clin Pharmacol. 2021 Aug;77(8):1095-1111. doi: 10.1007/s00228-021-03088-y. Epub 2021 Jan 29.